CoChat

Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA , a 24‐week, prospective, randomized, placebo‐controlled pilot trial

Open access
Harreiter, Jürgen, Just, Ivica, Leutner, Michael, Bastian, Magdalena, Brath, Helmut, Schelkshorn, Christian, Klepochova, Radka, Krššák, Martin, Kautzky‐Willer, Alexandra · 2021 · Diabetes, Obesity and Metabolism
Cited by 53

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aims: To investigate the potential synergistic effects of combined exenatide (EXE) and dapagliflozin (DAPA) versus (PLAC) placebo and DAPA on hepatocellular lipid (HCL) reduction after 24 weeks of treatment. Materials and methods: Thirty patients with type 2 diabetes were randomized to weekly EXE and daily DAPA (n = 16) or weekly PLAC and daily DAPA (n = 14). Inclusion criteria were glycated haemoglobin (HbA1c) 48 to 97 mmol/mol (6.5‐11%), age 18 to 75 years, body mass index (BMI) ≥25 kg/m 2 and metformin ≥1000 mg. The primary endpoint, HCL levels, were measured at baseline and after 24 weeks of treatment using magnetic resonance spectroscopy. Between‐group effects were analysed using general linear models, adjusted for baseline outcome variables, age, sex and BMI. Within‐group differences were assessed using a paired t ‐test. Results: After 24 weeks, HCLs were reduced in both treatment groups (absolute change from baseline: EXE + DAPA −4.4%, 95% confidence interval [CI] −8.2, −0.7, P < 0.05; PLAC + DAPA −3.9%, 95% CI −6.0, −1.7, P < 0.01; relative change: EXE + DAPA −35.6%, PLAC + DAPA −32.3%) with no difference between groups. Similar findings were observed for subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). HbA1c (EXE + DAPA −17.8 mmol/mol, [95% CI −24.8, −10.8], P <0.001; PLAC + DAPA −6.9 mmol/mol, [95% CI −10.5, −3.3], P = 0.001) and fasting glucose significantly decreased in both groups, although EXE + DAPA achieved better glycaemic control than PLAC + DAPA (adjusted difference: HbA1c −6.0 mmol/mol [95% CI −9.7, −2.2], P < 0.01). Body weight was reduced in both treatment groups (EXE + DAPA −7.3 kg, 95% CI −9.9, −4.8, P <0.001; PLAC + DAPA −4.6 kg, 95% CI −7.4, −1.8, P <0.01) with comparable results between groups. Changes in HCLs and weight, hip and waist circumference, VAT and SAT were positively associated. Conclusion: After 24 weeks, HCLs were significantly but comparably reduced in the EXE + DAPA and PLAC + DAPA groups, despite significantly better glycaemic control in the combined group EXE + DAPA. Changes in HCLs were associated with weight loss and reduction of visceral adiposity, but not with glucose control. Further studies are necessary to evaluate possible additional long‐term effects of a combined treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14319

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. 10.1007/s00125-016-3902-y · DOI · Paper page
  2. 10.1016/j.metabol.2020.154299 · DOI · Paper page
  3. 10.1111/liv.13751 · DOI · Paper page
  4. 10.1007/s00508-019-1471-z · DOI
  5. 10.1093/eurheartj/ehz687 · DOI · Paper page
  6. 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
  7. 10.2337/dc18-2460 · DOI · Paper page
  8. 10.1038/ajg.2010.18 · DOI · Paper page
  9. 10.1111/dom.13907 · DOI · Paper page
  10. 10.1016/j.metabol.2018.10.006 · DOI
  11. 10.1210/jc.2014-2242 · DOI
  12. 10.1152/ajpendo.00064.2004 · DOI · Paper page
  13. 10.1038/nmeth.2089 · DOI · Paper page
  14. 10.1007/s13300-020-00867-1 · DOI
  15. 10.1002/hep4.1019 · DOI · Paper page
  16. 10.1111/dom.13520 · DOI · Paper page
  17. 10.1016/S0140-6736(15)00803-X · DOI · Paper page
  18. 10.1111/hepr.12837 · DOI · Paper page
  19. 10.1002/edm2.131 · DOI
  20. 10.1002/dmrr.3292 · DOI · Paper page
  21. 10.1002/dmrr.2479 · DOI · Paper page
  22. 10.1111/j.1463-1326.2010.01216.x · DOI · Paper page
  23. 10.1001/jamainternmed.2019.2248 · DOI · Paper page
  24. 10.1016/j.cmet.2018.08.010 · DOI
  25. 10.1148/radiol.13121360 · DOI · Paper page

Cited by

See all 53

Metadata

Authors
Harreiter, J., Just, I., Leutner, M., Bastian, M., Brath, H., Schelkshorn, C., Klepochova, R., Krššák, M., & Kautzky‐Willer, A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2021-02-10
Volume
23
Issue
5
Pages
1129-1139
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3122632320
Cited by
53
References
12
FWCI
5.92
Type
journal article
Language
en
Open access
hybrid
Funders
AstraZeneca (ESR 15‐10882)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.